

DAFTAR PUSTAKA

1. Roju Lubis IT. JURNAL ILMIAH KOHESI Vol. 7 No. 1 Januari 2023. 2023;7(1):47–54.
2. Edition S. IDF - International Diabetes Federation. 2015.
3. Ian H. de Boer, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States. 2015;
4. KDOQI Guideline GLOBAL REPORT ON DIABETES.
5. Indonesia KKR. RISKESDAS 2018.
6. Organization WH. CKD in the General Population. 2021;vol;2020.
7. Wu AAT, Investigators M. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients : the MicroAlbuminuria Prevalence (MAP) Study. 2005;17–26.
8. Indonesian P, Registry R, Renal I, Indonesia PN, Kesehatan D, Kesehatan D, et al. 8 th Report Of IRR 2015. 2016;
9. Zelmanovitz T, Gerchman F, Balthazar APS, Thomazelli FCS, Matos JD, Canani LH. Diabetology & Metabolic Diabetic nephropathy. 2009;17:1–17.
10. Neuen BL, Chadban SJ, Demaio AR, Johnson DW, Perkovic V, Prince R, et al. Chronic kidney disease and the global NCDs agenda. 2017;1–5.
11. Gheith O, Farouk N, Nampoory N, Halim MA, Al-otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. 2016;5(1):49–56.
12. ES HS, Decroli E, Afriwardi A. Faktor Risiko Pasien Nefropati Diabetik Yang Dirawat Di Bagian Penyakit Dalam Rsup Dr. M. Djamil Padang. J Kesehat Andalas. 2018;7(2):149.
13. Qi W, Li Q, Gordin D, King GL, King GL. Preservation of renal function in chronic diabetes by enhancing glomerular glucose metabolism. 2018;2.
14. Zhang G, Darshi M, Sharma K. The Warburg Effect in Diabetic Kidney Disease. Semin Nephrol. 1924;38(2):111–20.
15. Tu C, Wang L WL. The Role of PKM2 in Diabetic Microangiopathy. 2022;(May):1405–12.
16. Factors VG, Disease G. HHS Public Access. 2019;437–61.

17. Baelde HJ, Eikmans M, Lappin DWP, Doran PP, Hohenadel D, Brinkkoetter P t, et al. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. *Kidney Int* [Internet]. 2007;71(7):637–45.
18. Abdulrahman SB, Saleh ES, Saeedi SM. Study of the reliability of serum vascular endothelial growth factor and its soluble receptor as markers of diabetic nephropathy in type 2 diabetes patients. *Int J Health Sci (Qassim)*. 2022;6:4922–34.
19. Fu J, Wu I hsien, King GL, Fu J, Shinjo T, Li Q, et al. Regeneration of glomerular metabolism and function by podocyte pyruvate kinase M2 in diabetic nephropathy Regeneration of glomerular metabolism and function by podocyte pyruvate kinase M2 in diabetic nephropathy. 2022;7(5).
20. Vlado Perkovic, Sunil V Badve GLB. Treatment of diabetic kidney disease. *Biomed Pharmacother*. 1992;46(1):46–7.
21. Qi W, Keenan HA, Li Q, Ishikado A, Kannt A, Sadowski T, et al. Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction. *Nat Publ Gr* [Internet]. 2017;23(6):753–62.
22. Prospective UK, Study D. UKPDS - Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). 1998;352(Ukpbs 33):837–53.
23. Sas KM, Iii FCB, Pennathur S, Sas KM, Kayampilly P, Byun J, et al. Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications. 2016;1(15).
24. Saenz-pipaon G, Echeverria S, Orbe J. Urinary Extracellular Vesicles for Diabetic Kidney Disease Diagnosis. 2021
25. Rajala A, Soni K, Rajala RVS. Metabolic and Non-metabolic Roles of Pyruvate Kinase M2 Isoform in Diabetic Retinopathy. *Sci Rep* [Internet]. 2020;1–12. Available from: <http://dx.doi.org/10.1038/s41598-020-64487-2>

26. Liu H, Takagaki Y, Kumagai A, Kanasaki K, Koya D. The PKM2 activator TEPP-46 suppresses kidney fibrosis via inhibition of the EMT program and aberrant glycolysis associated with suppression of HIF-1 α accumulation. 2021;12(5):697–709.
27. Domigan CK, Warren CM, Antanesian V, Happel K, Ziyad S, Lee S, et al. Autocrine VEGF maintains endothelial survival through regulation of metabolism and autophagy. 2015;2236–48.
28. Eremina V, Cui S, Gerber H, Ferrara N, Haigh J, Nagy A, et al. Vascular Endothelial Growth Factor A Signaling in the Podocyte-Endothelial Compartment Is Required for Mesangial Cell Migration and Survival. (14):724–35.
29. Zhang Z, Deng X, Liu Y, Liu Y, Sun L, Chen F. PKM2 , function and expression and regulation. Cell Biosci. 2019;1–25.
30. Macisaac RJ, Ekinci EI, Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Diseases. 2014;63(2 SUPPL.2):S39–62.
31. Dimitrov BD, Perna A, Ruggerenti P, Remuzzi G. Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual level. Kidney International. 2003;63(5):1924–33.
32. Bertelsen LB, Søvsø E, Hansen S, Ruf S, Laustsen C, Sadowski T. Hyperpolarized pyruvate to measure the influence of PKM2 activation on glucose metabolism in the healthy kidney. 2021;(February):2–11.
33. Park YS, Han JH, Park JH, Choi JS, Kim SH, Kim HS. Pyruvate Kinase M2 : A New Biomarker for the Early Detection of Diabetes-Induced Nephropathy.
34. Yokoyama M, Tanuma N, Shibuya R, Shiroki T. Pyruvate kinase type M2 contributes to the development of pancreatic ductal adenocarcinoma by regulating the production of metabolites and reactive oxygen species. 2018;881–91.
35. Liu L, Xu H, Zhao H JC, Liu L, Xu H, Zhao H, Jiang C. STEAP4 inhibits HIF-1 α PKM2 signaling and reduces high glucose induced apoptosis of retinal vascular endothelial cells. Diabetes, Metabolic Syndrome and Ob.pdf.

36. Dwyer BK, Gorman M, Carroll IR, Druzin M. Urinalysis vs urine protein - Creatinine ratio to predict significant proteinuria in pregnancy. *Journal of Perinatology*. 2008;28(7):461–7.
37. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. *American Journal of Kidney Disease*. 2007;49(2 SUPPL.2).
38. Molitch ME, DeFronzo RA, Franz J, Keane WF, Mogensen CE, Parving HH, Steffes W. Nephropathy in Diabetes. *Diabetologie*. 2019;15(6):568–72.
39. Alquraishi M, Puckett DL, Alani DS, Humidat AS, Frankel VD, Donohoe DR, et al. Free Radical Biology and Medicine Pyruvate kinase M2 : A simple molecule with complex functions. *Free Radicology Biology Medicine*. 2019;143:176–92.
40. Xu J, Jiang C, Wang X, Geng M, Peng Y, Guo Y, et al. Upregulated PKM2 in Macrophages Exacerbates Experimental Arthritis via STAT1 Signaling. 2020;
41. Gosling P, Czyz J, Nightingale P, Manji M. Microalbuminuria in the intensive care unit: Clinical correlates and association with outcomes in 431 patients. *Critical Care Medicine*. 2006;34(8):2158–66.
42. Milik A, Hryniewicz E. On translation of LD, IL and SFC given according to IEC-61131 for hardware synthesis of reconfigurable logic controller. *IFAC Proc Vol*. 2014;19(1):4477–83.
43. Viswanathan G, Upadhyay A. Assessment of Proteinuria. *Advance of Chronic Kidney Disease*. 2011;18(4):243–8.
44. Chiu C fang, Weng J ru, Lee S lun, Wu C yung, Chu P chen. OSU-A9 induced-reactive oxygen species cause cytotoxicity in duodenal and gastric cancer cells by decreasing phosphorylated nuclear pyruvate kinase M2 protein levels. *Biochem Pharmacology*. 2020;174:113811.
45. Sizemore ST, Zhang M, Cho JH, Sizemore GM, Hurwitz B, Kaur B, et al. Pyruvate kinase M2 regulates homologous recombination- mediated DNA double-strand break repair. *Cell Res*. 2018;
46. Yang P, Li Z, Li H, Lu Y, Wu H, Li Z. Pyruvate kinase M2 accelerates pro-inflammatory cytokine secretion and cell proliferation induced by lipopolysaccharide in colorectal cancer. *Cell Signal*. 2015;27(7):1525–32.

47. Li Q, Leng K, Liu Y, Sun H, Gao J, Ren Q, et al. The impact of hyperglycaemia on PKM2-mediated NLRP3 inflammasome / stress granule signalling in macrophages and its correlation with plaque vulnerability : an in vivo and in vitro study. *Metabolisme*. 2020;107:154231.
48. Ravender R, Roumelioti ME, Schmidt Dw, Unruh ML, Argyropoulos C. Chronic kidney disease in the older adult patient with diabetes. *Journal on Clinical Medicine*. 2024;13(348):1-20
49. Fabre L, Rangel EB. Age-related markers and predictors of diabetic kidney disease in type 2 diabetes patients: a retrospective cohort study. *Therapeutic Advances in Endocrinology and Metabolism*. 2024. Vol 15:1-20
50. Shi L, Xue Y, Yu X, Wang Y, Hong T, Li X et al. Prevalence and risk factors of chronic kidney disease in patients with type 2 diabetes in China: Cross-Sectional study. *JMIR Public Health Survei*. 2024;10(e54429):1-18
51. Wan KM, Hairi NN, Mustapha F, Yusoff MFM, Rifin HM, Ismail M, et al. Prevalence of diabetic kidney disease and the associated factors among patients with type 2 diabetes in a multi-ethnic Asian country. *Scientific Reports*. 2024.14;7074:1-10
52. Hauteclorque A, Ragot S, Slaoui Y, Gand E, Miot A, Sosner P, et al. The influence of sex on renal funtional decline in people with type 2 diabetes. *Diabtic Medicine*. 2014;31:1121-28
53. Piani F, Melena I, Tommerdahl KL, Nokoff N, Nelson RG, Pavkov ME, et al. Sex-related differences in diabetic kidney disease: a review on the mechanisms and potential therapeutic implications. *J Diabetes Complications*. 2021; 35(4):107841(1-25).
54. White MC, Fleeman R, Arnold AC. Sex differences in the metabolic effects of the renin-angitensin system. *Biology of sex differences*. 2019. 10;31:1-18.
55. Gohar EY, Pollock DM. Sex specific contributions of endothelin to hypertension. *Curr Hypertens Rep*. 2019. 20(7):58,1-12
56. Muscogiuri G, Barrea L, Annuziata G, Vecchiarini M, Orio F, Somma CD, et al. Water intake keeps type 2 diabetes away? Focus on copeptin. *Springer Endocrine*. 2018. 62:292-298

57. Shi S, Ini L, Tian Y, Zhang B, Xiao J, Xu W, et al. Association of Obesity Indices with diabetic kidney disease and diabetic retinopathy in type 2 diabetes : A real world study. *Journal of Diabetes Research*. 2023;3819830:1-11
58. Wu Z, Yu S, Kang X, Liu Y, Xu Z, Li Z, et al. Association of visceral adiposity indeks with incident nephropathy and retinopathy: a cohort study in the diabetic population. *Cardiovascular Diabetology*. 2022. 21;23:1-9.
59. Novac C, Radulian G, Orzan A, Balgradean M. Short update on C-Peptide and its clinical value. *Journal of Clinical Medicine*. 2019;14(1):53-8
60. Despres JP. Body fat distribution and risk of cardiovascular disease an update. *AHA Journal*. 2012;126:1301-13
61. Kovesdy CP, Furth SL, Zoccali C. Obesity and kidney disease: hidden consequences of the epidemic. *Brazzilian Journal of Medical and Biological Research*. 2017;50(5)e6075:1-9
62. Jiang Y, Li J, Zhang J, Chen S. Serum VEGF as a predictive marker of glycemic control and diabetic nephropathy in Chinese older adults with type 2 diabetes mellitus. *Frontiers in Endocrinology*. 2023. 14;1274025:1-8
63. Liu W, Dua J, Ge X, Jiang X, Peng W, Zhao N, et al. The analysis of risk factors for diabetic kidney disease progression; a single center and cross-sectional experiment in Shanghai. *British Medical Journal*. 2022;12:e060238:1-9.
64. Zhang H, Yang S, Wang H, Farooqui HFM, Zhu W, Niu T, et al. Assessing the diagnostic utility of urinary albumin-to-creatinine rasio as a potential biomarker for diabetic mellitus patients. *Scientific Reports*. 2024;14;27198:1-9
65. Chu W, Ma LL, Li BX, Li MC. Clinical significance of vascular endothelial growth factor and endothelin-l in serum levels as novel indicators for predicting the progression of diabetic nephropathy. *European Journal of Inflammation*. 2023. Vol 21:1-7
66. Omar TA, El-Saeed GK, Khodeer SA, Dawood AA, El-Deeb SM, El-Shemy AM, et al. Vascular endothelial growth factor A with thow genetic variants for predication of mixed microvascular diabetic complications. *Egyptian Journal of Medical Human Genetics*. 2022;23(93):1-11
67. Zhang A, Fang H, Chen J, He L, Chen Y. Role of VEGF-A and LRG1 in

abnormal angiogenesis associated with diabetic nephropathy.

Frontiers in Physiology. 2020. Vol 11;1064:1-12

68. Tang WH, Hung WC, Wang CP, Wu CC, Hsuan CF, Yu TH, et al. The lower limit of reference of urinary albumin/creatinine ratio and the risk of chronic kidney disease progression in patients with type 2 diabetes mellitus. Frontiers in Endocrinology. 2022.Vol:13;858267:1-9
69. Aly MH, Arafat MA, Hussein OA, Elsaid HH, Hammed ARA. Study of angiopoietin-2 and vascular endothelial growth factor as markers of diabetic nephropathy onset in Egyptians diabetic patients with non-albuminuric state. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2019;13:1623-27
70. Li X, Wu TT, Chen J, Qiu W. Elevated expression levels of serum insulin-like growth factor-1, tumor necrosis factor- α and vascular endothelial growth factor 165 might exacerbate type 2 diabetic nephropathy. Journal of Diabetes Investigation. 2017;8:108-114
71. Yang B, Zhao XH, Ma GB. Role of serum β 2-microglobulin, glycosylated hemoglobin, and vascular endothelial growth factor levels in diabetic nephropathy. World Journal of Clinical Cases. 2022;10(23):8205-11

